admin

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 15, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S.

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 1, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today

- Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 - - Commenced Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, the first gene editing technology studied for Hepatitis B, in fourth

DURHAM, N.C. --(BUSINESS WIRE)--Mar. 21, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today

- PBGENE-HBV, the first and only clinical stage gene editing therapy for chronic hepatitis B – - Repeat dosing of PBGENE-HBV supported by definitive preclinical safety and toxicology studies - - ELIMINATE-B global Phase 1 study for chronic hepatitis B actively enrolling patients and will evaluate

- Potential first-in-class gene editing approach designed for dystrophin gene correction leading the body to produce a functional dystrophin protein applicable for majority of DMD patients (up to ~60%) - PBGENE-DMD restored dystrophin protein expression and significantly improved muscle function

- PBGENE-HBV is the first-ever investigational in vivo gene editing therapy cleared to enter clinical trials for the treatment of chronic hepatitis B in the United States ( U.S. ) – - IND clearance represents a significant regulatory milestone for PBGENE-HBV – - Company to expand its Phase 1

DURHAM, N.C. --(BUSINESS WIRE)--Feb. 24, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today

ELIMINATE-B Phase 1 dose finding study for chronic Hepatitis B executing on schedule with completion of first dose administration for cohort 1 (n=3 patients) PBGENE-HBV, the first LNP gene editing technology studied for Hepatitis B, was safe and well tolerated PBGENE-HBV demonstrated substantial

- Cindy Atwell , promoted to Chief Development and Business Officer- - Cassie Gorsuch , PhD, promoted to Chief Scientific Officer – DURHAM, N.C. --(BUSINESS WIRE)--Jan. 29, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS

- Treatment with ECUR-506 resulted in a complete clinical response from three months post exposure to the end of study (six months post exposure) - ECUR-506 was generally well tolerated with no significant clinical safety concerns - Insertion of a functional OTC gene through ARCUS in vivo gene

- Approval in Hong Kong marks the first clinical trial application clearance of an in vivo gene editing approach for chronic hepatitis B in Hong Kong and the second CTA approval for PBGENE-HBV in 2024 - ELIMINATE-B is a global, multi-site study now actively recruiting patients; expected to report

DURHAM, N.C. --(BUSINESS WIRE)--Nov. 21, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the

– PBGENE-HBV preclinical data reinforce safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study – – Phase 1 dose escalation and expansion trial, ELIMINATE-B, designed to assess safety and efficacy measured by

- Received approval for first Clinical Trial Application to advance PBGENE-HBV into first-in-human trials for treatment of chronic hepatitis B; additional global regulatory applications pending approval - Opened PBGENE-HBV phase 1 clinical program in Moldova ; patient screening underway with